1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Opportunity is currently forecasted; estimated post date July 17, 2026; application deadline September 18, 2026; estimated award date June 18, 2027.
NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices is a grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) that funds the translational development of innovative diagnostic and therapeutic medical devices.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93. 286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health 93.
121 -- Oral Diseases and Disorders Research Last Updated: May 13, 2026 View version history on Grants.
gov This Notice of Funding Opportunity (NOFO) is to encourage applications from investigators to advance the development and translation of next-generation technologies to prevent, monitor, diagnose, and treat disorders within the missions of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) and The Helping to End Addiction Long-term (HEAL) Initiatives.
Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.
For-profit organizations other than small businesses Federally recognized Native American tribal governments City or township governments Special district governments Public and Indian housing authorities Public and state institutions of higher education Private institutions of higher education Independent school districts Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Grantor contact information NIBIB Program Officers for RFA-EB-26-004 Please contact via e-mail. No documents are currently available.
Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Broad eligibility including small businesses, for-profit organizations, government entities, educational institutions, nonprofits, and foreign entities; clinical trial not allowed. Confirm the full requirements in the official notice before applying.
The current listing shows $6,000,000 total. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 18, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) is funded by National Institute of Biomedical Imaging and Bioengineering (NIBIB). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NIBIB Trailblazer Award for New and Early Stage Investigators (R21) is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). This grant is for early-stage researchers to pursue projects at the intersection of engineering and the physical sciences with life sciences. It is ideal for high-risk, high-impact medical device research where preliminary data is not required.
Small Business Innovation Research (SBIR)/ Small Business Technology Transfer... is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). The NIBIB Small Business Program supports the translation of cutting-edge technologies into commercial products to address critical healthcare challenges. These programs encourage research and development with a strong potential for technology commercialization.
NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) is sponsored by National Institutes of Health. NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) is a forecasted funding opportunity on Grants.gov from National Institutes of Health. Fiscal Year: 2027. Assistance Listing Number(s): 93.286, 93.121. <p>This Notice of Funding Opportunity (NOFO) is to encourage applications from investigators to advance the development and translation of next-generation technologies to prevent, monitor, diagnose, and treat disorders within the missions of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) and The Helping to End Addiction Long-term (HEAL) Initiatives. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FI...
NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) is sponsored by National Institutes of Health. NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) is a forecasted funding opportunity on Grants.gov from National Institutes of Health. Fiscal Year: 2027. Assistance Listing Number(s): 93.286, 93.121. <p>This Notice of Funding Opportunity (NOFO) is to encourage applications from investigators to advance the development and translation of next-generation technologies to prevent, monitor, diagnose, and treat disorders within the missions of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) and The Helping to End Addiction Long-term (HEAL) Initiatives. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FI...
The NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleThe April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read article